{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T05:29:31Z","timestamp":1786771771047,"version":"build-2736575974"},"reference-count":17,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2026]]},"DOI":"10.70352\/scrj.cr.26-0257","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T22:11:46Z","timestamp":1786745506000},"page":"n\/a","source":"Crossref","is-referenced-by-count":0,"title":["Adaptive Surgical Decision-Making for Synchronous Metastatic Pancreatic Cancer and Early Breast Cancer with a BRCA1 Pathogenic Variant: A Case Report"],"prefix":"10.70352","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1292-174X","authenticated-orcid":false,"given":"Takahiro","family":"Akahori","sequence":"first","affiliation":[{"name":"Department of Surgery, Nara Medical University, Kashihara, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyo","family":"Yokotani","sequence":"additional","affiliation":[{"name":"Department of Surgery, Nara Medical University, Kashihara, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Yoshizawa","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Nara Medical University, Kashihara, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Nara Medical University, Kashihara, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Nara Medical University, Kashihara, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Sho","sequence":"additional","affiliation":[{"name":"Department of Surgery, Nara Medical University, Kashihara, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Li S, Silvestri V, Leslie G, et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol 2022; 40: 1529\u201341.","DOI":"10.1200\/JCO.21.02112"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017; 317: 2402\u201316.","DOI":"10.1001\/jama.2017.7112"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019; 381: 317\u201327.","DOI":"10.1056\/NEJMoa1903387"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Golan T, Kanji ZS, Epelbaum R, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 2014; 111: 1132\u20138.","DOI":"10.1038\/bjc.2014.418"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017; 377: 523\u201333.","DOI":"10.1056\/NEJMoa1706450"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Akahori T, Sho M, Yanagimoto H, et al. Phase II study of the triple combination chemotherapy of SOXIRI (S-1\/oxaliplatin\/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma. Oncologist 2019; 24: 749\u2013e224.","DOI":"10.1634\/theoncologist.2018-0900"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Li X, Huang J, Wang F, et al. Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer. Ther Adv Med Oncol 2023; 15: 17588359231186029.","DOI":"10.1177\/17588359231186029"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Momtaz P, O\u2019Connor CA, Chou JF, et al. Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. Cancer 2021; 127: 4393\u2013402.","DOI":"10.1002\/cncr.33812"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Kindler HL, Hammel P, Reni M, et al. Overall survival results from the POLO trial: A phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol 2022; 40: 3929\u201339.","DOI":"10.1200\/JCO.21.01604"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Sokol ES, Pavlick D, Khiabanian H, et al. Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity. JCO Precis Oncol 2020; 4: 442\u201365.","DOI":"10.1200\/PO.19.00345"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) D\u2019Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst) 2018; 71: 172\u20136.","DOI":"10.1016\/j.dnarep.2018.08.021"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Li H, Liu Z-Y, Wu N, et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer 2020; 19: 107.","DOI":"10.1186\/s12943-020-01227-0"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Grant RC, Selander I, Connor AA, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 2015; 148: 556\u201364.","DOI":"10.1053\/j.gastro.2014.11.042"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Shindo K, Yu J, Suenaga M, et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol 2017; 35: 3382\u201390.","DOI":"10.1200\/JCO.2017.72.3502"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Kurian AW, Abrahamse P, Furgal A, et al. Germline genetic testing after cancer diagnosis. JAMA 2023; 330: 43\u201351.","DOI":"10.1001\/jama.2023.9526"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Iqbal J, Ragone A, Lubinski J, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2012; 107: 2005\u20139.","DOI":"10.1038\/bjc.2012.483"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Castro M, Vierkoetter K, Prager D, et al. Synchronous onset of breast and pancreatic cancers: Results of germline and somatic genetic analysis. Case Rep Oncol 2016; 9: 387\u201394.","DOI":"10.1159\/000447348"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.26-0257\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T05:23:50Z","timestamp":1786771430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.26-0257\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.26-0257","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"cr.26-0257"}}